X4 Pharmaceuticals (XFOR) Competitors $0.35 -0.02 (-4.77%) (As of 11:33 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XFOR vs. ELDN, BMEA, TCRX, ACB, SLN, ALEC, HURA, NLTX, ACRV, and APLTShould you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Eledon Pharmaceuticals (ELDN), Biomea Fusion (BMEA), TScan Therapeutics (TCRX), Aurora Cannabis (ACB), Silence Therapeutics (SLN), Alector (ALEC), TuHURA Biosciences (HURA), Neoleukin Therapeutics (NLTX), Acrivon Therapeutics (ACRV), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry. X4 Pharmaceuticals vs. Eledon Pharmaceuticals Biomea Fusion TScan Therapeutics Aurora Cannabis Silence Therapeutics Alector TuHURA Biosciences Neoleukin Therapeutics Acrivon Therapeutics Applied Therapeutics Eledon Pharmaceuticals (NASDAQ:ELDN) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do analysts prefer ELDN or XFOR? Eledon Pharmaceuticals currently has a consensus target price of $16.00, suggesting a potential upside of 267.82%. X4 Pharmaceuticals has a consensus target price of $2.88, suggesting a potential upside of 699.72%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00X4 Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk & volatility, ELDN or XFOR? Eledon Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Does the media favor ELDN or XFOR? In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 2 mentions for Eledon Pharmaceuticals and 1 mentions for X4 Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.44 beat X4 Pharmaceuticals' score of 1.31 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Eledon Pharmaceuticals Positive X4 Pharmaceuticals Positive Does the MarketBeat Community believe in ELDN or XFOR? X4 Pharmaceuticals received 48 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Eledon Pharmaceuticals an outperform vote while only 66.96% of users gave X4 Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEledon PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% X4 PharmaceuticalsOutperform Votes7566.96% Underperform Votes3733.04% Do insiders & institutionals have more ownership in ELDN or XFOR? 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 11.7% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, ELDN or XFOR? X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$116.54M-$2.01-2.16X4 PharmaceuticalsN/AN/A-$101.17M-$0.09-3.99 Is ELDN or XFOR more profitable? Eledon Pharmaceuticals' return on equity of -189.99% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -189.99% -28.17% X4 Pharmaceuticals N/A -236.19%-75.14% SummaryEledon Pharmaceuticals beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XFOR vs. The Competition Export to ExcelMetricX4 PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.31M$3.09B$5.20B$8.97BDividend YieldN/A1.84%5.23%4.04%P/E Ratio-3.9915.2685.7113.39Price / SalesN/A315.091,469.4286.49Price / CashN/A175.8435.2935.09Price / Book1.164.044.914.96Net Income-$101.17M-$41.68M$117.36M$224.10M7 Day Performance2.04%6.57%2.75%2.01%1 Month Performance-30.73%5.81%1.71%9.79%1 Year Performance-51.42%38.20%36.01%29.97% X4 Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XFORX4 Pharmaceuticals4.2512 of 5 stars$0.35-4.8%$2.88+713.8%-49.9%$60.26MN/A-3.9380Positive NewsGap UpELDNEledon Pharmaceuticals3.3551 of 5 stars$4.40-5.6%$16.00+263.6%+283.3%$262.85MN/A-2.2710Positive NewsHigh Trading VolumeBMEABiomea Fusion3.7022 of 5 stars$7.19-0.7%$39.36+447.5%-56.4%$260.56MN/A-1.7950Short Interest ↑TCRXTScan Therapeutics2.0212 of 5 stars$4.70-1.5%$12.00+155.3%-25.2%$250.84M$9.36M-4.41100Positive NewsACBAurora Cannabis0.3454 of 5 stars$4.57+0.4%N/A-1.1%$250.62M$200.35M-6.041,073SLNSilence Therapeutics3.7929 of 5 stars$8.15+2.9%$57.20+601.8%-39.6%$243.91M$16.25M-5.42100Analyst ForecastALECAlector4.3551 of 5 stars$2.49-3.9%$8.40+237.3%-54.9%$243.85M$61.51M-1.52270Short Interest ↓High Trading VolumeHURATuHURA BiosciencesN/A$5.73-12.7%$15.00+161.8%N/A$242.26MN/A0.00N/AGap UpHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$25.43-1.4%N/A+81.6%$238.99MN/A-8.1890High Trading VolumeACRVAcrivon Therapeutics2.6225 of 5 stars$7.61+0.4%$23.67+211.0%+68.7%$236.98MN/A-2.8358Positive NewsAPLTApplied Therapeutics4.3445 of 5 stars$2.03-76.3%$6.60+225.1%-27.7%$236.21M$9.99M-1.2630Analyst ForecastShort Interest ↑News CoverageHigh Trading Volume Related Companies and Tools Related Companies ELDN Competitors BMEA Competitors TCRX Competitors ACB Competitors SLN Competitors ALEC Competitors HURA Competitors NLTX Competitors ACRV Competitors APLT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XFOR) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
